-
Almorexant (INN), also
known by its
development code ACT-078573, is an
orexin antagonist,
acting as a
competitive antagonist of the OX1 and OX2 orexin...
-
phase 2 – half-life 1.5–3
hours ACT-335827 –
selective OX1
antagonist Almorexant (ACT-078573) – dual OX1 and OX2
antagonist –
development of the drug was...
- through, and GSK
instead launched a $3.3
billion deal to
market Actelion's
almorexant sleeping tablet,
which entered phase 3
medical trials before development...
- ACT-462206,
currently in
human clinical trials.
Another drug in development,
almorexant (ACT-078573) by Actelion, was
abandoned due to
adverse effects. Lemborexant...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
- Agonists:
Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313
Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542
Daridorexant Filorexant GSK-649868...
